Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
PONTE VEDRA, Fla., Oct. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant designed to...